The complex landscape of genetic alterations in mantle cell lymphoma

Seminars in Cancer Biology

Volumn 21, Issue 5, 2011, Pages 322-334

  Royo, Cristina ^a   Salaverria, Itziar ^a   Hartmann, Elena M ^b   Rosenwald, Andreas ^b   Campo, Elías ^a   Beà, Sílvia ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

CGH SNP array; Chromosomal translocation; Mantle cell lymphoma; Prognosis; Secondary genetic alteration

Indexed keywords

CYCLIN D1; MICROTUBULE ASSOCIATED PROTEIN;

BURKITT LYMPHOMA; CANCER SURVIVAL; CCND1 GENE; CCND2 GENE; CCND3 GENE; CELL CYCLE; CELL SURVIVAL; CHROMOSOME LOSS; CHROMOSOME TRANSLOCATION; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 2; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; DNA DAMAGE; FOLLICULAR LYMPHOMA; GENE; GENE INACTIVATION; GENE MUTATION; GENE TRANSLOCATION; HETEROZYGOSITY LOSS; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOGLOBULIN LIGHT CHAIN GENE; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; METAPHASE; ONCOGENE MYC; PROGNOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; SURVIVAL TIME; TUMOR SUPPRESSOR GENE;

CHROMOSOME ABERRATIONS; HUMANS; LYMPHOMA, MANTLE-CELL;

EID: 82555179127     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2011.09.007     Document Type: Review

References (94)

1. Swerdlow S., Campo E., Harris N., Jaffe E., Pileri S., Stein H., et al. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC, Lyon.
2. Jares P., Colomer D., Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007, 7:750-762.
3. Jares P., Campo E. Advances in the understanding of mantle cell lymphoma. Br J Haematol 2008, 142:149-165.
4. Perez-Galan P., Dreyling M., Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011, 117:26-38.
5. Rosenwald A., Wright G., Wiestner A., Chan W.C., Connors J.M., Campo E., et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, 3:185-197.
6. Hoster E., Dreyling M., Klapper W., Gisselbrecht C., Van H.A., Kluin-Nelemans H.C., et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008, 111:558-565.
7. Bea S., Ribas M., Hernandez J.M., Bosch F., Pinyol M., Hernandez L., et al. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 1999, 93:4365-4374.
8. Martin P., Chadburn A., Christos P., Weil K., Furman R.R., Ruan J., et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009, 27:1209-1213.
9. Orchard J., Garand R., Davis Z., Babbage G., Sahota S., Matutes E., et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 2003, 101:4975-4981.
10. Fernandez V., Salamero O., Espinet B., Sole F., Royo C., Navarro A., et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010, 70:1408-1418.
11. Ondrejka S.L., Lai R., Kumar N., Smith S.D., Hsi E.D. Indolent mantle cell leukemia: clinicopathologic variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica 2011, 96:1121-1127.
12. Eve H.E., Furtado M.V., Hamon M.D., Rule S.A. Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma. J Clin Oncol 2009, 27:e189-e190.
13. Ek S., Dictor M., Jerkeman M., Jirstrom K., Borrebaeck C.A. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood 2008, 111:800-805.
14. Mozos A., Royo C., Hartmann E., De J.D., Baro C., Valera A., et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009, 94:1555-1562.
15. Gruszka-Westwood A.M., Atkinson S., Summersgill B.M., Shipley J., Elnenaei M.O., Jain P., et al. Unusual case of leukemic mantle cell lymphoma with amplified CCND1/IGH fusion gene. Genes Chromosomes Cancer 2002, 33:206-212.
16. Salaverria I., Espinet B., Carrio A., Costa D., Astier L., Slotta-Huspenina L., et al. Multiple recurrent chromosomal breakpoints in mantle cell lymphoma revealed by a combination of molecular cytogenetic techniques. Genes Chromosomes Cancer 2008, 47:1086-1097.
17. Martin-Subero J.I., Odero M.D., Hernandez R., Cigudosa J.C., Agirre X., Saez B., et al. Amplification of IGH/MYC fusion in clinically aggressive IGH/BCL2-positive germinal center B-cell lymphomas. Genes Chromosomes Cancer 2005, 43:414-423.
18. Zhu C., Mills K.D., Ferguson D.O., Lee C., Manis J., Fleming J., et al. Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations. Cell 2002, 109:811-821.
19. Wlodarska I., Meeus P., Stul M., Thienpont L., Wouters E., Marcelis L., et al. Variant t(2;11)(p11;q13) associated with the IgK-CCND1 rearrangement is a recurrent translocation in leukemic small-cell B-non-Hodgkin lymphoma. Leukemia 2004, 18:1705-1710.
20. Komatsu H., Lida S., Yamamoto K., Mikuni C., Nitta M., Takahashi T., et al. A variant chromosome translocation at 11q13 identifying PRAD1/Cyclin D1 as the bcl-1 gene. Blood 1994, 84:1226-1231.
21. Espinet B., Salaverria I., Bea S., Ruiz-Xiville N., Balague O., Salido M., et al. Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. Genes Chromosomes Cancer 2010, 49:439-451.
22. Rocha C.K., Praulich I., Gehrke I., Hallek M., Kreuzer K.A. A rare case of t(11;22) in a mantle cell lymphoma like B-cell neoplasia resulting in a fusion of IGL and CCND1: case report. Mol Cytogenet 2011, 4:8.
23. Fu K., Weisenburger D.D., Greiner T.C., Dave S., Wright G., Rosenwald A., et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathological study based on gene expression profiling. Blood 2005, 106:4315-4321.
24. Gesk S., Klapper W., Martin-Subero J.I., Nagel I., Harder L., Fu K., et al. A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus. Blood 2006, 108:1109-1110.
25. Shiller S.M., Zieske A., Holmes H., Feldman A.L., Law M.E., Saad R. CD5-positive, cyclinD1-negative mantle cell lymphoma with a translocation involving the CCND2 gene and the IGL locus. Cancer Genet 2011, 204:162-164.
26. Herens C., Lambert F., Quintanilla-Martinez L., Bisig B., Deusings C., de L.L. Cyclin D1-negative mantle cell lymphoma with cryptic t(12;14)(p13;q32) and cyclin D2 overexpression. Blood 2008, 111:1745-1746.
27. Quintanilla-Martinez L., Slotta-Huspenina J., Koch I., Klier M., Hsi E.D., de L.L., et al. Differential diagnosis of cyclin D2+ mantle cell lymphoma based on fluorescence in situ hybridization and quantitative real-time-PCR. Haematologica 2009, 94:1595-1598.
28. Wlodarska I., Dierickx D., Vanhentenrijk V., Van R.K., Pospisilova H., Minnei F., et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood 2008, 111:5683-5690.
29. Salaverria I., Zettl A., Bea S., Moreno V., Valls J., Hartmann E., et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 2007, 25:1216-1222.
30. Hartmann E.M., Campo E., Wright G., Lenz G., Salaverria I., Jares P., et al. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood 2010, 116:953-961.
31. Tirier C., Zhang Y., Plendl H., Weber-Matthiesen K., Langer W., Heit W., et al. Simultaneous presence of t(11;14) and a variant Burkitt's translocation in the terminal phase of a mantle cell lymphoma. Leukemia 1996, 10:346-350.
32. Hao S., Sanger W., Onciu M., Lai R., Schlette E.J., Medeiros L.J. Mantle cell lymphoma with 8q24 chromosomal abnormalities: a report of 5 cases with blastoid features. Mod Pathol 2002, 15:1266-1272.
33. Vaishampayan U.N., Mohamed A.N., Dugan M.C., Bloom R.E., Palutke M. Blastic mantle cell lymphoma associated with Burkitt-type translocation and hypodiploidy. Br J Haematol 2001, 115:66-68.
34. Michaux L., Wlodarska I., Theate I., Stul M., Scheiff J.M., Deneys V., et al. Coexistence of BCL1/CCND1 and CMYC aberrations in blastoid mantle cell lymphoma: a rare finding associated with very poor outcome. Ann Hematol 2004, 83:578-583.
35. Oliveira F.M., Tone L.G., Simoes B.P., Rego E.M., Araujo A.G., Falcao R.P. Blastoid mantle cell lymphoma with t(2;8) (p12;q24). Leuk Lymphoma 2007, 48:2079-2082.
36. Salaverria I., Siebert R. The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective. J Clin Oncol 2011, 29:1835-1843.
37. Mossafa H., Damotte D., Jenabian A., Delarue R., Vincenneau A., Amouroux I., et al. Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis. Leuk Lymph 2006, 47:1885-1893.
38. Au W.Y., Horsman D.E., Gascoyne R.D., Viswanatha D.S., Klasa R.J., Connors J.M. The spectrum of lymphoma with 8q24 aberrations: a clinical, pathological and cytogenetic study of 87 consecutive cases. Leuk Lymph 2004, 45:519-528.
39. Au W.Y., Horsman D.E., Viswanatha D.S., Connors J.M., Klasa R.J., Gascoyne R.D. 8q24 translocations in blastic transformation of mantle cell lymphoma. Haematologica 2000, 85:1225-1227.
40. Au W.Y., Gascoyne R.D., Viswanatha D.S., Connors J.M., Klasa R.J., Horsman D.E. Cytogenetic analysis in mantle cell lymphoma: a review of 214 cases. Leuk Lymph 2002, 43:783-791.
41. Wlodarska I., Pittaluga S., Hagemeijer A., Wolf-Peeters C., Van Den B.H. Secondary chromosome changes in mantle cell lymphoma. Haematologica 1999, 84:594-599.
42. Ott G., Kalla J., Ott M.M., Schryen B., Katzenberger T., Muller J.G., et al. Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood 1997, 89:1421-1429.
43. Bea S., Campo E. Secondary genomic alterations in non-Hodgkin's lymphomas: tumor-specific profiles with impact on clinical behavior. Haematologica 2008, 93:641-645.
44. Bentz M., Plesch A., Bullinger L., Stilgenbauer S., Ott G., Muller-Hermelink H.K., et al. t(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer 2000, 27:285-294.
45. Monni O., Oinonen R., Elonen E., Franssila K., Teerenhovi L., Joensuu H., et al. Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma. Genes Chromosomes Cancer 1998, 21:298-307.
46. Martinez-Climent J.A., Vizcarra E., Sanchez D., Blesa D., Marugan I., Benet I., et al. Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma. Blood 2001, 98:3479-3482.
47. Allen J.E., Hough R.E., Goepel J.R., Bottomley S., Wilson G.A., Alcock H.E., et al. Identification of novel regions of amplification and deletion within mantle cell lymphoma DNA by comparative genomic hybridization. Br J Haematol 2002, 116:291-298.
48. Jarosova M., Papajik T., Holzerova M., Dusek L., Pikalova Z., Lakoma I., et al. High incidence of unbalanced chromosomal changes in mantle cell lymphoma detected by comparative genomic hybridization. Leuk Lymph 2004, 45:1835-1846.
49. Ferrer A., Salaverria I., Bosch F., Villamor N., Rozman M., Bea S., et al. Leukemic involvement is a common feature in mantle cell lymphoma. Cancer 2007, 109:2473-2480.
50. Camacho E., Hernandez L., Hernandez S., Tort F., Bellosillo B., Bea S., et al. ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. Blood 2002, 99:238-244.
51. Greiner T.C., Dasgupta C., Ho V.V., Weisenburger D.D., Smith L.M., Lynch J.C., et al. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc Natl Acad Sci U S A 2006, 103:2352-2357.
52. Kohlhammer H., Schwaenen C., Wessendorf S., Holzmann K., Kestler H.A., Kienle D., et al. Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. Blood 2004, 104:795-801.
53. Rubio-Moscardo F., Climent J., Siebert R., Piris M.A., Martin-Subero J.I., Nielander I., et al. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 2005, 105:4445-4454.
54. Schaffner C., Idler I., Stilgenbauer S., Dohner H., Lichter P. Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc Natl Acad Sci U S A 2000, 97:2773-2778.
55. Schraders M., Pfundt R., Straatman H.M., Janssen I.M., van Kessel A.G., Schoenmakers E.F., et al. Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization. Blood 2005, 105:1686-1693.
56. Tagawa H., Karnan S., Suzuki R., Matsuo K., Zhang X., Ota A., et al. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 2005, 24:1348-1358.
57. Flordal T.E., Ichimura K., Collins V.P., Walsh S.H., Barbany G., Hagberg A., et al. Detailed assessment of copy number alterations revealing homozygous deletions in 1p and 13q in mantle cell lymphoma. Leuk Res 2007, 31:1219-1230.
58. Rinaldi A., Kwee I., Taborelli M., Largo C., Uccella S., Martin V., et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol 2006, 132:303-316.
59. Vater I., Wagner F., Kreuz M., Berger H., Martin-Subero J.I., Pott C., et al. GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma. Br J Haematol 2009, 144:317-331.
60. Bea S., Salaverria I., Armengol L., Pinyol M., Fernandez V., Hartmann E.M., et al. Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. Blood 2009, 113:3059-3069.
61. Kawamata N., Ogawa S., Gueller S., Ross S.H., Huynh T., Chen J., et al. Identified hidden genomic changes in mantle cell lymphoma using high-resolution single nucleotide polymorphism genomic array. Exp Hematol 2009, 37:937-946.
62. Halldorsdottir A.M., Sander B., Goransson H., Isaksson A., Kimby E., Mansouri M., et al. High-resolution genomic screening in mantle cell lymphoma--specific changes correlate with genomic complexity, the proliferation signature and survival. Genes Chromosomes Cancer 2011, 50:113-121.
63. Pinyol M., Bea S., Pla L., Ribrag V., Bosq J., Rosenwald A., et al. Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis. Blood 2007, 109:5422-5429.
64. Honma K., Tsuzuki S., Nakagawa M., Tagawa H., Nakamura S., Morishima Y., et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 2009, 114:2467-2475.
65. Navarro A., Bea S., Fernandez V., Prieto M., Salaverria I., Jares P., et al. MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in Mantle cell lymphomas. Cancer Res 2009, 69:7071-7078.
66. Coquelle A., Pipiras E., Toledo F., Buttin G., Debatisse M. Expression of fragile sites triggers intrachromosomal mammalian gene amplification and sets boundaries to early amplicons. Cell 1997, 89:215-225.
67. Stephens P.J., McBride D.J., Lin M.L., Varela I., Pleasance E.D., Simpson J.T., et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009, 462:1005-1010.
68. Hernandez L., Bea S., Pinyol M., Ott G., Katzenberger T., Rosenwald A., et al. CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. Cancer Res 2005, 65:2199-2206.
69. Kotake Y., Zeng Y., Xiong Y., DDB1-CUL4 MLL1 mediate oncogene-induced p16INK4a activation. Cancer Res 2009, 69:1809-1814.
70. Pinyol M., Hernandez L., Martinez A., Cobo F., Hernandez S., Bea S., et al. INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. Am J Pathol 2000, 156:1987-1996.
71. Tort F., Hernandez S., Bea S., Martinez A., Esteller M., Herman J.G., et al. CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. Blood 2002, 100:4602-4608.
72. Tort F., Hernandez S., Bea S., Camacho E., Fernandez V., Esteller M., et al. Checkpoint kinase 1 (CHK1) protein and mRNA expression is downregulated in aggressive variants of human lymphoid neoplasms. Leukemia 2005, 19:112-117.
73. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790.
74. Bruce S., Leinonen R., Lindgren C.M., Kivinen K., Hlman-Wright K., Lipsanen-Nyman M., et al. Global analysis of uniparental disomy using high density genotyping arrays. J Med Genet 2005, 42:847-851.
75. O'shea D., O'Riain C., Gupta M., Waters R., Yang Y., Wrench D., et al. Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. Blood 2009, 113:2298-2301.
76. Kawamata N., Ogawa S., Zimmermann M., Kato M., Sanada M., Hemminki K., et al. Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood 2008, 111:776-784.
77. Katzenberger T., Kienle D., Stilgenbauer S., Holler S., Schilling C., Mader U., et al. Delineation of distinct tumour profiles in mantle cell lymphoma by detailed cytogenetic, interphase genetic and morphological analysis. Br J Haematol 2008, 142:538-550.
78. Parry-Jones N., Matutes E., Morilla R., Brito-Babapulle V., Wotherspoon A., Swansbury G.J., et al. Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: a study of 60 cases by FISH. Br J Haematol 2007, 137:117-124.
79. Halldorsdottir AM, Lundin A, Murray F, Mansouri L, Knuutila S, Sundstrom C, et al. Impact of TP53 mutation and 17p deletion in mantle cell lymphoma. Leukemia 2011. E Publised.
80. Zenz T., Mertens D., Dohner H., Stilgenbauer S. Importance of genetics in chronic lymphocytic leukemia. Blood Rev 2011, 25:131-137.
81. Espinet B., Sole F., Pedro C., Garcia M., Bellosillo B., Salido M., et al. Clonal proliferation of cyclin D1-positive mantle lymphocytes in an asymptomatic patient: an early-stage event in the development or an indolent form of a mantle cell lymphoma?. Hum Pathol 2005, 36:1232-1237.
82. Nodit L., Bahler D.W., Jacobs S.A., Locker J., Swerdlow S.H. Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Hum Pathol 2003, 34:1030-1034.
83. Hernandez L., Fest T., Cazorla M., Teruya-Feldstein J., Bosch F., Peinado M.A., et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 1996, 87:3351-3359.
84. Greiner T.C., Moynihan M.J., Chan W.C., Lytle D.M., Pedersen A., Anderson J.R., et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 1996, 87:4302-4310.
85. Hangaishi A., Ogawa S., Qiao Y., Wang L., Hosoya N., Yuji K., et al. Mutations of Chk2 in primary hematopoietic neoplasms. Blood 2002, 99:3075-3077.
86. Morin R.D., Johnson N.A., Severson T.M., Mungall A.J., An J., Goya R., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010, 42:181-185.
87. Pasqualucci L., Dominguez-Sola D., Chiarenza A., Fabbri G., Grunn A., Trifonov V., et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011, 471:189-195.
88. Mullighan C.G., Zhang J., Kasper L.H., Lerach S., Payne-Turner D., Phillips L.A., et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011, 471:235-239.
89. Greif P.A., Yaghmaie M., Konstandin N.P., Ksienzyk B., Alimoghaddam K., Ghavamzadeh A., et al. Somatic mutations in acute promyelocytic leukemia (APL) identified by exome sequencing. Leukemia 2011, 25:1519-1522.
90. Tiacci E., Trifonov V., Schiavoni G., Holmes A., Kern W., Martelli M.P., et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011, 364:2305-2315.
91. Steidl C., Shah S.P., Woolcock B.W., Rui L., Kawahara M., Farinha P., et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011, 471:377-381.
92. Puente X.S., Pinyol M., Quesada V., Conde L., Ordonez G.R., Villamor N., et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011, 475:101-105.
93. Fabbri G., Rasi S., Rossi D., Trifonov V., Khiabanian H., Ma J., et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011, 208:1389-1401.
94. Lecluse Y., Lebailly P., Roulland S., Gac A.C., Nadel B., Gauduchon P. t(11;14)-positive clones can persist over a long period of time in the peripheral blood of healthy individuals. Leukemia 2009, 23:1190-1193.